Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vir Biotechnology Inc (VIR)

Vir Biotechnology Inc (VIR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 926,573
  • Shares Outstanding, K 139,125
  • Annual Sales, $ 74,210 K
  • Annual Income, $ -521,960 K
  • EBIT $ -549 M
  • EBITDA $ -529 M
  • 60-Month Beta 1.34
  • Price/Sales 12.34
  • Price/Cash Flow N/A
  • Price/Book 1.15

Options Overview Details

View History
  • Implied Volatility 247.16% (+75.06%)
  • Historical Volatility 74.54%
  • IV Percentile 97%
  • IV Rank 41.72%
  • IV High 520.93% on 11/04/25
  • IV Low 51.19% on 07/31/25
  • Expected Move (DTE 9) 0.17 (2.60%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 477
  • Volume Avg (30-Day) 788
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 17,221
  • Open Int (30-Day) 11,237
  • Expected Range 6.38 to 6.72

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.61
  • Number of Estimates 5
  • High Estimate -0.16
  • Low Estimate -0.80
  • Prior Year -0.76
  • Growth Rate Est. (year over year) +19.74%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.32 +23.12%
on 11/19/25
7.06 -7.22%
on 12/08/25
+1.18 (+21.97%)
since 11/10/25
3-Month
4.75 +37.89%
on 09/16/25
7.06 -7.22%
on 12/08/25
+1.42 (+27.68%)
since 09/10/25
52-Week
4.16 +57.64%
on 08/11/25
14.45 -54.67%
on 01/08/25
-1.54 (-19.04%)
since 12/10/24

Most Recent Stories

More News
Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference

Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference...

VIR : 6.55 (-1.65%)
Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile

SOLSTICE trial data demonstrate that 66% of chronic hepatitis delta participants receiving a monthly dose of tobevibart and elebsiran achieved undetectable HDV RNA at Week 48 ...

VIR : 6.55 (-1.65%)
Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the Jefferies 2025 London Healthcare Conference on Tuesday, November...

VIR : 6.55 (-1.65%)
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results

- ECLIPSE 1 enrollment completed approximately two months ahead of schedule; ECLIPSE 2 and ECLIPSE 3 progressing with strong enrollment momentum, with topline data for all three studies expected in the...

VIR : 6.55 (-1.65%)
Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta

– ECLIPSE 1 estimated date of last participant reaching primary endpoint (primary completion) in the fourth quarter of 2026, and topline data expected in the first quarter of 2027 ...

VIR : 6.55 (-1.65%)
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025

Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2025, on November 5, 2025....

VIR : 6.55 (-1.65%)
Vir Biotechnology (VIR) Gets a Buy from H.C. Wainwright

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Vir Biotechnology, with a price target of $15.00. The company’s shares opened today at $5.73.Elevate Your...

VIR : 6.55 (-1.65%)
Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer

– Phase 1 clinical trial designed to assess the safety, pharmacokinetics and preliminary efficacy of VIR-5500 in combination with androgen receptor pathway inhibitors in first-line mCRPC ...

VIR : 6.55 (-1.65%)
Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD’s The Liver Meeting® 2025

– Week 48 endpoint results from the SOLSTICE Phase 2 clinical study evaluating tobevibart alone or in combination with elebsiran for chronic hepatitis delta to be presented ...

VIR : 6.55 (-1.65%)
Vir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 23 rd ...

VIR : 6.55 (-1.65%)

Business Summary

Vir Biotechnology Inc. is a clinical-stage immunology company. It is focused on combining immunologic insights to treat and prevent serious infectious diseases. The company's development pipeline consists of product candidates targeting the hepatitis B virus, influenza A, human immunodeficiency virus...

See More

Key Turning Points

3rd Resistance Point 7.19
2nd Resistance Point 7.04
1st Resistance Point 6.80
Last Price 6.55
1st Support Level 6.40
2nd Support Level 6.25
3rd Support Level 6.00

See More

52-Week High 14.45
Fibonacci 61.8% 10.52
Fibonacci 50% 9.30
Fibonacci 38.2% 8.09
Last Price 6.55
52-Week Low 4.16

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar